ETFMG Alternative Harvest (NYSE: MJ ) What is ETFMG Alternative Harvest? An ETF that acceptance of various uses of the cannabis plant such as pharmaceuticals, biotechnology and life sciences, JesusTrade Score: Buy Scale Score: Low (3/10) Portfolio Hold: Yearly Hold Fundamental Reasoning: The following below are the top 10 holding for MJ: GW...
NYSE:PFE looks to be heading up towards the 40 area very soon .
www.cftc.gov COT's managed fund traders flipping bullish on natural gas near the bottom. Nonreportables closing longs, a good sign because they're supposed to be the always wrong crowd. Entry below current price and S/R level because it may be a bad bet. Entry may be missed but it's okay
#AlnylamPharmaceuticals just hit the strong resistance. Volume is above the average but RSI is below the trendline. Negative divergence is on weekly
Novavax's Nanoflu isn't your typical new drug-- it's a whole new pharmaceutical technology. So it's hard to overstate how important today's positive Phase 3 clinical trial result is. Positive Phase 3 trial data this morning suggest that Novavax's Virus-Like Particle (VLP)-based flu vaccines will be much more effective than existing egg-based vaccines. When you...
Bristol-Myers Squibb says it has seen no major business disruptions and expects no decrease in global demand for its drugs this year. That means the 3.5% dividend yield should stay stable, and BMY is a great value at 1.3 PEG. BMY also just got FDA approval for a multiple sclerosis drug, which could turn out to be a pretty big deal. Most of the market has been...
These are my personal views as i FEEL there might be a minor reversals may be due to anticipated profit bookings.... Mainly cos retail traders dont really let their profits run completely... But i see biiig smart money interest in this stock and sector... My views for this stock is for more than 3- 6 months... good returns can be expected...
The downwards pattern in the RSI suggest we may break that trend soon and move upwards. Also there is strong support around $27.85 if the downwards trend on the RSI continues and the price hits $27.85 I think there is a buying opportunity but we also see there is resistance on the upside at $37.37ish. Not a bad time to long Pfizer specially if we get close to the...
4H Chart Explanation: - Price broke the Weekly Ascending Trendline and went down to the Support Zone. - Price bounced from there, developing a Pullback. - After the up correction is finished, price wil go down to the next Support Zones. Weekly Vision: Daily Vision:
In my experience trendly / volatile stocks have a tendency to have significant long term reversals from wedges and general downtrendline breaks. Extremely interested to see where this goes, if it does end up breaking out bullishly. Company could begin a new bull run, or simply reach target and mean revert.
Parameters : Position Size : %1 Risk/Reward Ratio : 3 Stop-Loss : 275 Goal : 284.2 *** NOTE : If opens too high , Goal is 290.8.
Congress's coronavirus stimulus deal reached Friday night included a provision requiring health insurers to bear the full cost of coronavirus test kits and to waive copays. The federal government will pay the cost for the uninsured. This will probably hurt health insurers Monday, though it might be good for service providers. Here's another piece of bad news:...
Normally when we see a such massive drops in equity, the on balance volume also trends down. OBV is reaching a 2-year high, as we have dropped over 30%. This divergence suggests pharmaceuticals could outperform as the market starts consolidating. ---- Regarding the volatility due to Medicare for All proposal, supported by Bernie Sanders, it seems highly...
As the PPH dropped 15% below the 200sma, OBV barely moved lower compared to the drop. (Between purple vertical lines). This is considered a Bullish Divergence . Now with a strong pullback, we are half way to reach past highs; but this time with an OBV we have not yet seen since Feb, 2018. Ready to buy the dip!
BEAT is your prototypical aggressive growth stock- Strong future growth potential with good earning and revenue track record ... If you can overlook its debt level. This beast was tamed for a while after its share price skyrocketed from $25 to almost $80 , but it is ready to unleash its fury again. But first, I think the pullback is in the store facing key...